EGFR and non-small cell lung carcinoma: This analysis indicates that PFS is longer in patients with EGFR mutation-positive NSCLC when treated with erlotinib (12.4 months) or gefitinib (9.4 months), compared with conventional chemotherapy (5.6 months).